LSN Summer Reading Series Chapter 7: “Establishing a Web Presence”

By Shaoyu Chang, MD, MPH,  Senior Research Analyst, LSN

Shaoyu 10*10If investors find interest in your slide deck and executive summary, what is the next thing they typically do? They look you up on the internet. A fundraising entrepreneur would not want to miss out on this opportunity to connect with interested investors. As a key component of your branding and messaging strategy, a good website provides a fully integrated and interactive package of information about your story, technology, team, and most recent updates. In this week’s edition of summer reading series, we will explore the issues a life science executive must consider when creating a strong web presence.

Chapter 7 of The Life Science Executive’s Fundraising Manifesto, “Establishing a Web Presence,” discusses what makes a simple and effective website, whether to do it yourself or hire a web designer, how to employ search engine optimization to drive traffic to your site, and the importance of constantly managing and updating your content.

Click here to download/print the PDF.

Over the past few weeks, we have laid the groundwork for a marketing campaign. Join us next week as we go outbound in Chapter 8, “Leveraging Cloud Infrastructure to Manage an Outbound Campaign,” where we identify useful tools for managing your outbound activities.

Enjoyed the preview? Buy now from Amazon.com or Barnes & Noble

Bookcover-Front

Back to Boston and Bigger than Ever: RESI Conference on September 16th

By Lucy Parkinson, Senior Research Manager, LSN 

lucy 10*10The first Redefining Early Stage Investments (RESI) Conference took place on September 16, 2013, and two years later, following highly successful events in San Francisco and Houston, we return to Boston for the sixth RESI Conference. With new and returning sponsors including Johnson & Johnson Innovation JLABS, Charles River Laboratories, McDermott Will & Emory, and Wuxi AppTec, we expect this event to be the largest RESI so far, with more content and more meetings than ever.

The RESI Conference Series was founded with the goal of creating meetings based on a common fit. Our experience shows that starting with fit, and then finding a targeted alignment between entrepreneurs and investors, leads to compelling conversations; RESI’s mission is to provide a venue for those conversations to begin and develop. By connecting early stage life science fundraising executives with the right investors, RESI is where qualified fundraising relationships arise.

LSN’s CEO, Dennis Ford, says, “We want to inundate the attendees of RESI Boston with more amazing opportunities than they can handle, including one-on-one investor meetings, firsthand information from RESI’s early stage investor panels, and tactical guidance from fundraising workshops—because if we’re doing that, we’re doing our job. We want to provide a huge amount of relevant content to everyone, on one day. RESI’s goal is to give the fundraising CEOs and scientist entrepreneurs in this early stage investment world as much value as possible.”

RESI Boston offers entrepreneurs the opportunity to schedule up to 16 meetings with investors through the RESI Partnering Platform; and in addition to these face-to-face meetings, 20+ panels and workshops focused on various aspects of fundraising and investment will provide platforms for investors and industry veterans to share valuable insights with fundraising entrepreneurs.

If you’d like to be part of the largest RESI ever, you can register before 7/31/2015 at the Early Bird Rate here.

RESI-Boston-wp

RESI@TMCX Medtech Family Offices Panel

By Shaoyu Chang, MD, MPH,  Senior Research Analyst, LSN

Shaoyu 10*10On the heels of last weeks Biotech Family Offices Panel Video from RESI @TMCX we bring you our Medtech Family offices video. Hear firsthand accounts from these family office investors in the medical device space regarding the types and stages of companies they are looking for and how to go about getting in touch with them.

Click on the video below to hear the views of these family office speakers for yourself.

 

LSN Summer Reading Series Chapter 6: “Branding and Messaging”

By Michael Quigley, Director of Research, LSN

mike-2Last week we discussed how to determine where your company fits within your marketplace. Once you have completed that process, the next step in a fundraising campaign is to develop your marketing materials. In this week’s edition of the summer reading series, we describe the importance of and what constitutes a strong set of marketing materials in the life science fundraising world. While your team and your technology are what will ultimately secure an allocation, having marketing collateral that clearly and concisely communicates your message will help you tremendously in getting in the door with investors.

Chapter 6 of The Life Science Executive’s Fundraising Manifesto discusses in depth the different pieces of marketing collateral you should be putting into the marketplace and how to develop everything from your logo to your pitch deck.

Click here to download/print the PDF.

Join us next week for Chapter 7: “Building a Web Presence,” where we take an even deeper dive into how best to use a website as a fundraising tool.

Enjoyed the preview? Buy now from Amazon.com or Barnes & Noble

Bookcover-Front

Family Offices and Walled Gardens

By Dennis Ford, Founder & CEO, LSN 

Dennis book

The LSN mantra is that raising capital is a numbers game.  To succeed, you must find investors that are a fit for your product and stage of development, go global rather than restricting yourself to your local region, and target all ten categories of early stage life science investor rather than restricting your view to one source of capital.

Every few months it seems that someone in the investment world has an epiphany that they must create a global family office network. The idea always seems compelling and usually involves a plan to sponsor small, intimate conferences that target companies seeking investors. The network creators begin courting the venture community and healthcare CEOs with descriptions of the family offices that allegedly bought in and will attend these conferences — and the price to appear at them is often  a lot of money. The attending fundraising CEOs theoretically benefit from getting in front of the new hot category of investor, and it’s suggested that the family offices will participate in such a small meeting in return for the chance to trade strategies, tactics, and evaluations with other similar entities.  This model and concept is all about getting special access, which sounds almost too good to be true…right?

Having been involved in capital fundraising for decades, I have seen this model surface countless times. Many of these family office networks can provide examples of the allocations and partnerships their network has generated; the question is how many and how much?  This model has been called a “walled garden” because of the illusion it perpetuates of a bevy of family office players  banding together in a closed, almost secret network who can be accessed by paying a fee for a chance to connect with the  right contact. While these networks may include at least a handful of contacts with whom a dialogue can be established, I have yet to encounter a walled garden family office firm that employs any research staff to track what the family offices’ investing interests are. This is an absolute necessity for staying up to date on investment mandates, which are ever-changing—without accurate data and an understanding of the possible fit between your company and the investor, contact information has tenuous value.

Additionally, most family offices (institutions with over $1 billion in assets under management that form one of the categories of investors that LSN tracks) would rather not be a part of any organization that would compromise their anonymity; these firms are well known for a predilection for stealth mode and a preference for flying under the radar. Because they have access to large sums of capital they do not need to form syndicates, so have little to gain from the walled garden model.  As for the opportunity to share information and strategies behind a virtual secret wall, family offices already source from each other and don’t need third parties or service providers to facilitate this. Also, while syndication does occur regionally and within close networks of like-minded family offices, it doesn’t seem relevant on a global scale simply because of the low ratio of family offices to fundraising CEO’s. The larger Family Office conferences can be useful to fundraising executives, offering the possibility of contact with a handful of family office representatives, but these bigger venues  are primarily populated by family office service providers who are also being charged high fees to attend.

LSN tracks 970 family offices globally, has identified 180 as private life science investors, and has forged a deeper relationship with 70, which use LSN as a trusted sourcing vehicle. This is also true of the other nine categories of investors that we track. Many family offices see us as a trusted source that has proven our worth and provides a compelling and augmenting service offering that can be vetted quickly for no cost. But we recognize that focusing too much on one category of investors, especially a group like family offices, can be counterproductive, which is why over three years we have built up a true global network of over 5000 early stage investors covering ten categories.

RESI@TMCx Biotech Family Office Panel

By Michael Quigley, Director of Research, LSN

mike-2Earlier this month Life Science Nation’s RESI Conference at the TMCx in Houston was home to a panel of representatives and experts in the Family office world who spoke to how their groups go about sourcing and making investments in the therapeutic space. Key topics discussed include the position of family offices in the investment ecosystem, the differences and similarities between family offices and other investors, how family offices go about identifying opportunities, and what these particular groups are looking for right now.

Click on the video below to hear the views of these family offices speaker for yourself.

LSN Summer Reading Series Chapter 5: “Knowing Who and What You Are, and Where You Fit”

By Shaoyu Chang, MD, MPH,  Senior Research Analyst, LSN

Shaoyu 10*10In this latest edition of the summer reading series, we will be explaining the importance of understanding where your opportunity fits within the marketplace. Knowing who you are and how you compare with other companies in the space is crucial in determining the investors to whom you should be reaching out, what you should be highlighting in your marketing materials, and, in some cases, whether you need to “pivot,” or change, your commercialization plan.

Chapter 5 of The Life Science Executive’s Fundraising Manifesto, “Knowing Who and What You Are, and Where You Fit,” discusses how to define yourself and your market, as well as the importance of being able to pivot after receiving feedback and how to identify when it is strategically relevant to do so.

Click here to download/print the PDF.

We hope this text proves to be informative. Join us next week for Chapter 6: “Branding and Messaging”, for some tactical tips on how to build a brand for your company.

Enjoyed the preview? Buy now from Amazon.com or Barnes & Noble

Bookcover-Front